We have examined the eects of human papilloma virus (HPV) E6 proteins on interferon (IFN) signaling. Here we show that expression of the`malignant' HPV-18 E6 in human HT1080 cells results in inhibition of Jak-STAT activation in response to IFN-a but not IFN-g. This inhibitory eect is not shared by the`benign' HPV-11 E6. The DNA-binding and transactivation capacities of the transcription factor ISGF3 are diminished in cells expressing HPV-18 E6 after IFN-a treatment as a result of decreased tyrosine phosphorylation of Tyk2, STAT2 and STAT1. However, HPV-18 E6 does not aect the induction of tyrosine phosphorylation and DNA-binding of STAT1 by IFN-g. In addition, HPV E6 proteins physically interact with Tyk2. This interaction takes place preferably with HPV-18 E6 and to a lesser extent with HPV-11 E6. The E6/Tyk2 interaction requires the JH 6 -JH 7 domains of Tyk2, which are important for Tyk2 binding to the cytoplasmic portion of IFN-a receptor 1 (IFNAR1). These ®ndings demonstrate an inhibitory role of HPV-18 E6 in the IFN-a-induced Jak-STAT pathway, which may be explained, at least in part, by the ability of E6 to interact with and impair Tyk2 activation.
Introduction
In humans, HPV infections often result in the formation of a variety of warts, i.e. papillomas, on skin or at anogenital organs. Among the total of 77 HPV subtypes identi®ed so far, HPV-16 and 18 are two subtypes that retain the strongest tumorigenic activity, and belong to the`high risk' group of HPVs. Some of the HPV encoding proteins, i.e. E6, E7 and E5 from the`high risk' HPVs have been shown to exhibit transforming activities (for review see Howley, 1996; zur Hausen, 1996) . It has been demonstrated that E6 protein from the`high risk' but not the`low risk' HPVs has the capacity to bind to the tumor suppressor p53 and promote its degradation through ubiquitinmediated proteolysis (Howley, 1996) . Expression of HPV-16 E6 alone is able to immortalize human mammary epithelial cells, or induce anchorageindependent growth of NIH3T3 cells (Howley, 1996; zur Hausen, 1996) . It has also been shown that HPV-16 E6 inhibits the serum-and calcium-induced dierentiation of human keratinocytes (Sherman and Schlegel, 1996) . Despite all these functions, other roles of E6, particularly the ones from the`high risk' HPVs, in HPV-associated diseases and malignant tumor formation still remain elusive.
Interferons (IFNs) are a family of cytokines that exhibit strong antiviral and antiproliferative activities (for review see Vilcek and Sen, 1996) . The signal transduction pathway used by IFNs has become a prototype for signaling by many other cytokines (for review see Stark et al., 1998) . The binding of IFNs to their receptors elicits multiple signal transduction pathways which lead to the activation of dierent sets of genes. A consensus cis-acting DNA sequence that confers inducibility by IFN-a/b is present in the 5' anking regions of all IFN-a/b-stimulated genes (ISGs) examined so far. This sequence is termed the IFNstimulated response element (ISRE). Stimulation with type I IFN (i.e. IFN-a/b) induces binding to ISRE of a factor known as IFN-stimulated gene factor-3 (ISGF3), which is required for the transcriptional activation of ISRE-containing genes. Active ISGF3 is composed of four functional subunits. Three of these proteins are called signal transducer and activators of transcription (STAT). They are 113 (STAT2), 91 (STAT1a), 84 (STAT1b) kDa in size, collectively termed ISGF3a proteins and reside in the cytoplasm of unstimulated cells as monomers. In cells stimulated with IFN-a/b, ISGF3a proteins are tyrosine-phosphorylated, multimerize, translocate to the nucleus and bind DNA in the presence of a fourth protein, ISGF3g, a 48 kDa DNA-binding protein (Bluyssen et al., 1996) , thereby forming the ISGF3 active complex. Tyrosine phosphorylation of ISGF3a proteins is mediated by activated cytoplasmic tyrosine kinases of the Janus (JAK) family, Jak1 and Tyk2, which associate with the receptor cytoplasmic tails (for review see Pellegrini and Dusanter-Fourt, 1997) . Activated Jaks become autophosphorylated and subsequently phosphorylate the receptor on speci®c tyrosine residues, which function as docking sites for the src homology 2 (SH2) domain of STATs.
Similarly, type II IFN (i.e. IFN-g) induces transcription through binding to the >IFN-gamma activation site (GAS) by activated STAT1 homodimers (for review see Darnell, 1997) . A single phosphorylation site on STAT1 at tyrosine 701 , which is mediated through Jak1 and Jak2 (Pellegrini and Dusanter-Fourt, 1997) , appears to be both necessary and sucient to mediate nuclear translocation, DNAbinding activity, and transcriptional activation by IFN-g. In addition to tyrosine phosphorylation, serine 727 phosphorylation of STAT1 is also required for maximal transcriptional activation (Darnell, 1997; Kovarik et al., 1998) .
The use of IFNs for the treatment of HPVassociated cervical intraepithelial neoplasia (CIN) or cervical cancer has been under clinical trials (for review see Rockley and Tyring, 1995; Shah and Howley, 1996) . Despite the satisfactory results in some of the clinical studies, IFN treatment is still far from widespread therapy against HPV infections. The success of IFNs appears to be largely dependent on the type of HPV and the immune response of the patients. Warts that are caused by the`low risk' HPV-6 or 11 have high response rates to IFN treatment, whereas those, which are caused by thè high risk' HPV-16 or 18, do not (Stellato, 1992; Trofatter, 1991) . Considering the signi®cance of HPV-associated disease in the human population and the little knowledge about the nature of HPV resistance to the IFN treatment, we sought to examine a role of HPV-18 oncoproteins in IFN signaling. In this paper, we provide strong evidence that HPV-18 E6 functions as a negative regulator of the Jak-STAT pathway activated by IFN-a through the inhibition of Tyk2 activation. We also show that Tyk2 physically associates with E6. The Tyk2/E6 interaction is stronger with HPV-18 E6 than HPV-11 E6 and requires the JH 6 -JH 7 domains of Tyk2, which are necessary for Tyk2 binding to IFNAR1. These novel ®ndings may reveal important mechanisms utilized by`high risk' HPVs to counteract IFN treatment.
Results

Inhibition of ISGF-3 DNA-binding in response to IFN-a
To investigate a possible role of HPV-18 E6 oncoprotein in the JAK-STAT signaling, we used the human ®brosarcoma epithelial-like HT1080 cells stably expressing the HPV-18 E6 (Labrecque and Matlashewski, 1995) . HT1080 cells transfected with the neomycin resistant gene (control cells) and HT1080 cells expressing HPV-18 E6 were stimulated with IFN-a for various periods of time. DNA-binding of ISGF3 was analysed by electrophoretic mobility shift assays (EMSAs) using a dsDNA oligonucleotide, which encompasses the ISRE of the ISG-15 gene (Reich and Darnell, 1989) . Formation of a DNA/ protein complex with the speci®city and mobility of ISGF3 was induced in both HT1080 cell lines at 30, 60 and 90 min after IFN-a treatment ( Figure 1A , top panel, lanes 2 ± 4 and 7 ± 9). ISGF3 DNA-binding was *®vefold higher in control cells than in cells expressing HPV-18 E6 (compare lanes 2 ± 4 with 7 ± 9). To con®rm the identity of the induced DNAprotein complex, antibodies to STAT-1a ( Figure 1A , bottom panel, lanes 12 and 17), STAT-2 (lanes 13 and 18) and phosphotyrosine (PTyr) (lanes 14 and 19) were added in the EMSA reactions. As a control for nonspeci®c binding, mouse IgG 1 antibody was used (lanes 11 and 16). ISGF3 complex formation was abolished by the anti-STAT and anti-PTyr antibodies demonstrating that the induced DNA-binding complex consisted of tyrosine phosphorylated STAT1a and STAT2.
To eliminate the possibility that dierences in ISGF3 DNA-binding were due to clonal variations, we examined ISGF3 DNA-binding in two separate polyclonal populations of HT1080 cells transfected with the HPV-18 E6 gene. Similar to the E6 expressing HT1080 clone, ISGF3 DNA-binding by IFN-a was inhibited in both E6 polyclonal populations of HT1080 cells ( Figure 1B , compare lane 2 with 5 and 8, lane 3 with 6 and 9) demonstrating that the eect of HPV-18 E6 was not clone speci®c. 9) . Cell extracts were then analysed for DNA-binding using a 32 P-labeled dsDNA ISRE oligonucleotide from ISG-15 gene promoter. A 100-excess of unlabeled dsDNA oligonucleotide was added in the cold competition reactions (lanes 5, 10, 15 and 20) . For supershift assays, extracts from 30 min after IFN-a stimulation were preincubated with 2 mg of mouse IgG 1 (lanes 11 and 16), antiSTAT1a (lanes 12 and 17), anti-STAT2 (lanes 13 and 18) and anti-PTyr (lanes 14 and 19) antibodies. (B) HT1080 control cells (lanes 1 ± 3 and 10) and two independent polyclonal populations of HT1080 cells expressing HPV-18 E6 (Pool I, lanes 4 ± 6; Pool II, lanes 7 ± 9) were stimulated with 1000 IU/ml of IFN-a for 30 (lanes 2, 5 and 8) and 60 min (lanes 3, 6, 9 and 10). ISGF3 DNA-binding was then examined using 32 P-labeled ISRE from the ISG-15 gene promoter. A 100-fold excess of unlabeled ISRE oligonucleotide was added in the cold competition reaction in lane 10
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Activation with IFN-a may also lead to STAT1 homodimerization and binding to the GAS DNA element of IFN-inducible genes (Pine et al., 1994) . Based on this, we then examined STAT1 DNAbinding in cell extracts from IFN-a-treated cells by EMSA using a dsDNA oligonucleotide that encompassed the GAS sequence of the promoter region of the IFP-53 gene (Strehlow et al., 1993) Figure 2B , lanes 2 ± 4). The same level of induction was observed in HT1080 cells expressing the HPV-18 E6 ( Figure 2B , lanes 7 ± 9) suggesting that E6 has little eect, if any, on STAT1 DNA-binding by IFN-g. Supershift assays with antibodies to STAT1a (p91) ( Figure 2B , lanes 12 and 17), STAT2 (p113) (lanes 13 and 18) and PTyr (lanes 14 and 19) identi®ed tyrosine phosphorylated STAT1a as the component of IFN-g inducible DNAprotein complex.
Induction of ISGF3 or STAT1 DNA-binding by IFNs is normal in cells expressing the HPV-11 E6 Next, we wished to examine whether inhibition of ISGF3 DNA-binding by E6 diers among the benign and transforming subtypes of HPV. To address this question, HT1080 cells were transfected with the HPV-11 E6 gene and the neomycin resistant gene. Thirty clones were isolated and analysed for expression of HPV-11 E6 by Northern blotting (data not shown). One of the clones with the highest HPV-11 E6 RNA levels was chosen for further analysis. Stimulation with IFN-a resulted in induction of ISGF3 DNA-binding, which was equal to HT1080 control cells ( Figure 3A , compare lanes 2 ± 5 with 7 ± 9). In addition, an equal induction of STAT1 DNA-binding was observed when HT1080 control cells and cells expressing HPV-11 E6 were treated with IFN-g ( Figure 2B , lanes 2 ± 4 and 7 ± 9). Similar data were obtained when HT1080 polyclonal populations expressing HPV-11 E6 were used (data not shown). These ®ndings suggest that inhibition of ISGF3 DNA-binding is not a property of thè benign' HPV-11 E6.
HPV-18 E6 decreases transactivation of IFN-inducible genes
Next we examined whether the inhibition of To further verify the above ®ndings, we performed transient transfection assays using the luciferase reporter gene under the control of the ISRE from the promoter of the ISG-15 gene (Pine et al., 1994) . Induction of luciferase activity was then assessed in both cell lines after stimulation with IFN-a ( Figure  4B ). Five independent experiments revealed a 30% inhibition of ISG-15 promoter transactivation by HPV-18 E6 in response to IFN-a, and this eect was statistically signi®cant (P50.05). Similar data were obtained when polyclonal populations of HPV-18 E6 expressing HT1080 cells were used in the transient transfections (data not shown). These results are consistent with the decreased levels of ISG-15 RNA expression in Figure 4A and demonstrate the negative eect of HPV-18 E6 on IFN-a-induced gene transactivation.
IFN-a-induced tyrosine phosphorylation of Tyk2 and STAT2 is decreased in cells expressing HPV-18 E6
Since ISGF3 DNA-binding requires tyrosine phosphorylation of STAT1 and STAT2, we reasoned that tyrosine phosphorylation of these proteins might be aected by HPV-18 E6. To this end, STAT2 phosphorylation ( Figure 5A ) was examined by a combination of immunoprecipitation with an anti-STAT2 speci®c antibody and immunoblotting with anti-Ptyr antibodies before (lanes 1 and 4) and after stimulation with IFN-a (lanes 2, 3, 5 and 6). These experiments showed that IFN-a-induced tyrosine phosphorylation of STAT2 ( Figure 5A , upper panel), when normalized to STAT2 protein levels by immunoblotting (lower panel), was *®vefold less in cells expressing the HPV-18 E6 compared to control cells (compare lane 2 with 5 and 3 with 6). Similar observations were made for tyrosine phosphorylation of STAT1 (data not shown).
Since STAT2 phosphorylation requires activation of Tyk2, we then sought to examine whether Tyk2 phosphorylation is aected by HPV-18 E6. Immunoprecipitation of Tyk2 from IFN-induced cell extracts and immunoblotting with anti-Ptyr antibodies ( Figure  5B , top panel) revealed that tyrosine phosphorylation of Tyk2 was decreased *®vefold in cells expressing HPV-18 E6 compared to control cells (compare lane 2 with 5 and 3 with 6). In these experiments, the amount of immunoprecipitated Tyk2 was equal between the two cell lines as judged by immunoblot analysis ( Figure  5B , bottom panel). This data suggests that Tyk2 activation is impaired in HPV-18 E6 cells and this may account for the defective tyrosine phosphorylation of STAT2.
Interaction of Tyk2 with GST-E6 fusion proteins
Considering the ability of E6 to interact with several cellular proteins (reviewed by Rapp and Chen, 1998), we thought that inhibition of Tyk2 activation might have been due to its interaction with E6. This possibility was further investigated by performing pull down assays of Tyk2 with puri®ed GST-fusion proteins of HPV-11 and HPV-18 E6 ( Figure 6 ). Incubation of cell extracts with the GST-fusion proteins and pull down assays with glutathionesepharose ( Figure 6A ) revealed an interaction between the endogenous Tyk2 (top panel) and HPV-18 E6 (lanes 2 and 3) or HPV-11 E6 (lanes 4 and 5). The interaction between the two proteins was observed even after IFN-a stimulation for 10 min (lanes 3 and 5). The identity of Tyk2 protein was veri®ed by comparing Tyk2 levels in cell extracts from 2fTGH (lane 7) and U1A cells (lane 6), a mutant cell line lacking Tyk2 (Velazquez et al., 1992) . These experiments also showed a higher amount of Tyk2 to interact with HPV-18 E6 compared to HPV-11 E6 (compare lanes 2 and 3 with 4 and 5). In addition, IFN-a treatment did not aect the interaction of Tyk2 with either of the GST-E6 fusion proteins (lanes 3 and 5) indicating that this interaction may take place independently of Tyk2 activation. It is noteworthy that in similar experiments neither STAT2 nor STAT1 interacted with E6 in vitro (data not shown).
To further analyse the Tyk2/E6 interaction, we examined their association using a wild type (wt) and the catalytically inactive K930I form of Tyk2. To better monitor the interaction, Tyk2 proteins were overexpressed in HeLa cells using the vaccinia virus/T7 system (Fuerst et al., 1986) (Figure 6B ). Pull down assays of wt Tyk2 (lanes 2 ± 4) or Tyk2 K930I mutant (lanes 6 ± 8) with equal amounts of GST-HPV-18 E6 3 and 7) or GST-HPV-11 E6 (lanes 4 and 8) and immunoblot analysis with anti-Tyk2 antibodies con®rmed the Tyk2/E6 interaction and the ability of mutant Tyk2 to co-precipitate with each of the E6 proteins (lanes 7 and 8) . In addition, we observed that a higher amount (*®vefold) of Tyk2 co-precipitated with GST-HPV-18 E6 than GST-HPV-11 E6 (compare lane 3 with 4 and 7 with 8). 
Co-immunoprecipitation of Tyk2 and E6 proteins
The Tyk2/E6 interaction was further veri®ed by coimmunoprecipitation. To this end, we used wt Tyk2 and E6 proteins bearing the vesicular stomatitis virus glycoprotein (VSV-G) (Gauzzi et al., 1997) and FLAG epitope in their C-terminus end respectively. VSV-GTyk2 and FLAG-E6 proteins were co-transfected in HeLa cells using the vaccinia virus/T7 system and their expression levels were detected by immunoblotting with either anti-VSV-G (Figure 7 , top row) or anti-FLAG antibodies (second from the top row). In these experiments we noticed that expression of FLAG-11E6 was much higher than FLAG-18E6 when equal amounts of DNA were used (Figure 7 , second from the top row, compare lanes 2 and 3 with 6 and 7). Equal expression HPV-18 and HPV-11 E6 proteins was achieved only when the amount of transfected FLAG-11E6 DNA was decreased tenfold (lanes 4 and 5). In contrast to E6, no dierences in VSV-GTyk2 protein expression levels were observed (Figure 7 , top row).
The interaction of VSV-G-Tyk2 with FLAG-E6 proteins was then monitored by immunoprecipitation with anti-VSV-G antibodies followed by immunoblot analysis with anti-VSV-G (third row) and anti-FLAG antibodies (bottom row). These experiments demonstrated that Tyk2 interacts with both types of E6 (third and bottom rows, compare lanes 3 and 7). However, the interaction of Tyk2 with HPV-11 E6 was not detected (bottom row, lane 5) upon conditions that expression of FLAG-18E6 was equal to FLAG-11E6 (compare lanes 3 and 5) demonstrating that HPV-18 E6 binds to Tyk2 with a higher anity than HPV-11 E6. Immunoblot analysis with anti-VSV-G antibodies showed that an equal amount of VSV-G-Tyk2 was immunoprecipitated in all reactions (third row, lanes 3, 5 and 7).
The HPV-18 E6/Tyk 2 interaction requires the JH 6 -JH 7 domains of Tyk2
To better understand the molecular basis of Tyk2/E6 interaction, we then sought to identify the domain(s) of Tyk2 required for binding to E6 (Figure 8 ). The approach taken was to use either full length VSV-GTyk2 (lanes 1 and 2) , a VSV-G-Tyk2 truncated protein consisting of the N-terminus part of Tyk2 only (lanes 3 and 4) and VSV-G-Tyk2 proteins lacking either the ®rst 287 (lanes 5 and 6) or 496 amino acids (lanes 7 and 8) from the N-terminus. These VSV-G-Tyk2 forms were overexpressed in HeLa cells by the vaccinia virus/ T7 system and extracts were used in pull down assays with puri®ed GST-HPV-18 E6 fusion protein ( Figure  8A ). These experiments showed that the ®rst 287 amino acids of Tyk2, which encompass the JH 6 and JH 7 domains of Tyk2, are required for the interaction with E6.
The Jaks have been implicated in binding to the cytoplasmic portions of IFN receptors (Colamonici et al., 1994a,b; Kohlhuber et al., 1997) through their JH 6 - Figure 5 Inhibition of STAT2 and Tyk2 tyrosine phosphorylation by HPV-18 E6. HT1080 control cells (A and B, lanes 1 ± 3) and HT1080 cells expressing HPV-18 E6 (A and B, lanes 4 ± 6) were stimulated with 1000 IU/ml of IFN-a (A and B) for 15 (lanes 2 and 3) or 30 min (lanes 3 and 6). Cell extracts (*500 mg) were used for immunoprecipitation with either anti-STAT2 antibody (A) or anti-Tyk2 antibody (B). Samples were subjected to immunoblotting ®rst with anti-PTyr antibodies (A and B, top panel) followed by immunoblot analysis with anti-STAT2 (A, bottom panel) or anti-Tyk2 antibody (B, bottom panel) Figure 6 Interaction of Tyk2 with E6 in vitro. (A) Cell extracts (500 mg of protein) of HT1080 cells before (lanes 1, 2 and 4) and after 10 min stimulation with 1000 IU/ml of IFN-a (lanes 3 and 5) were mixed with 1 mg of puri®ed GST alone (lane 1) or GST-E6 fusion proteins from HPV-18 (lanes 2 and 3) and HPV-11 (lanes 4 and 5). Extracts were pulled down with glutathionesepharose beads and subjected to immunoblot analysis with antibodies to Tyk2. Lanes 6 and 7, 50 mg of protein extracts from U1A and 2fTGH cells respectively used as controls to Tyk2 . (B) Wild type Tyk2 (lanes 1 ± 4) or the catalytically inactive Tyk2 K930I mutant (lanes 5 ± 8) was overexpressed in HeLa S3 cells using the vaccinia/T7 system. Cell extracts (100 mg of protein) from each infection/transfection were incubated with 1 mg puri®ed GST (lanes 2 and 6), GST-HPV-18 E6 (lanes 3 and 7) or GST-HPV-11 E6 (lanes 4 and 8), pulled down with glutathionesepharose beads and subjected to Western blotting with antibodies against Tyk2. Lanes 1 and 5 represent 10% of the total input of Tyk2 for each pull-down reaction JH 7 domains (Richter et al., 1998) . To con®rm this observation, full length VSV-G-Tyk2 and truncated VSV-G-Tyk2 D(1 ± 287) were overexpressed in HeLa cells by vaccinia virus/T7 system. Pull down experiments with a puri®ed GST-fusion protein encompassing amino acids 465 ± 557 from cytoplasmic part of IFN receptor (Colamonici et al., 1994a,b) resulted in interaction with Tyk2 but not Tyk2D(1 ± 287) mutant ( Figure 8B ). This result shows that HPV-18 E6 interacts with the domains of Tyk2 required for binding to IFN receptor. Similar experiments showed the lack of interactions between the E6 proteins and IFNAR1 (data not shown).
Discussion
In this paper we have examined the eects of E6 proteins on IFN signaling. The approach we have taken was to establish cell lines from the human HT1080 cells stably expressing the E6 gene. HT1080 cells were derived from a ®brosarcoma but subsequent subcultivation eliminated the growth of ®broblasts and favored proliferation of epithelial cells (Hay et al., 1994) . For this reason, HT1080 were shown to be a suitable system to study the functions of E6 protein (Labrecque and Matlashewski, 1995) . Stimulation with IFN-a resulted in inhibition of binding of the ISGF3 complex to the ISRE DNA found in the promoter of the IFNinducible genes ( Figure 1A ). This eect appeared to be speci®c for ISGF3, since DNA-binding of other transcription factors induced by IFN-a (i.e. IRF-1, IRF-2) was not modi®ed by HPV-18 E6 (data not shown). In addition, induction of ISGF3 DNAbinding by IFN-a was not modi®ed by the presence of HPV-11 E6 (Figure 3) suggesting that inhibition of Jak-STAT activation is a property of thè malignant' HPV-18 E6. In contrast to IFN-a, induction of STAT1 DNA-binding ( Figure 2B ) and ISG RNA expression (data not shown) by IFN-g were not aected by HPV-18 E6 suggesting a speci®c role for HPV-18 E6 in type I IFN signaling.
Phosphorylation of human STAT1 on tyrosine 701 and human STAT2 on tyrosine 690 are necessary and sucient for binding to DNA as part of the ISGF3 complex (Darnell, 1997; Stark et al., 1998) . Immunoblot analyses with anti-PTyr antibodies demonstrated a diminished phosphorylation of STAT2 ( Figure 5A ) and Tyk2 ( Figure 5B ) by HPV-18 E6 in response to IFN-a. We also noticed some dierences in the levels of inhibition of ISGF3 DNA-binding and transactivation by the HPV-18 E6. Speci®cally, IFN-a stimulation Figure 7 Co-immunoprecipitation of Tyk2 and E6 proteins. FLAG-18E6 (lanes 2 and 3) or FLAG-11E6 protein (lanes, 4, 5, 6 and 7) was expressed either alone (lanes 2, 4 and 6) or together with VSV-G-Tyk2 (lanes 3, 5 and 7) in HeLa cells using the vaccinia virus/T7 system. Expression of E6 and Tyk2 proteins was ®rst detected by immunoblot analysis of 50 mg of whole cell extracts with either anti-VSV-G (top row) or anti-FLAG mouse monoclonal antibody (second row). Tyk2/E6 interaction was detected by immunoprecipitation of 1 mg of protein extracts with 2.5 mg a mouse monoclonal anti-VSV-G antibody followed by immunoblot analysis with either anti-VSV-G (third row) or anti-FLAG monoclonal antibody (bottom row). As control mock transfected HeLa cells were used (lane 1). The amounts (mg) of transfected DNA for each of the vectors are indicated on the top 4) and truncated VSV-GTyk2 lacking either the ®rst 287 [D(1 ± 287), lanes 5 and 6] or the ®rst 496 [D(1 ± 4960), lanes 7 and 8] amino acids were expressed in HeLa S3 cells by the vaccinia/T7 system. Cell extracts (100 mg of protein) were used for pull down with 1 mg of puri®ed GST-HPV-18 E6 (lanes 2, 4, 6 and 8). Samples were subjected to immunoblot analysis with anti-VSV-G antibody. As control, 5% of the total input for each Tyk2 pull-down reaction was used (lanes 1, 3, 5 and 7). (B) In vitro interaction of Tyk2 with IFNAR1. Full length wild type VSV-G-Tyk2 (lane 2) or D(1 ± 287) VSV-G-Tyk2 expressed by vaccinia/T7 in HeLa S3 cells (100 mg of protein extracts) were used for pull down with 1 mg of puri®ed GST-IFNAR1 (aa 465 ± 557) fusion protein. Samples were analysed by immunoblotting using anti-VSV-G antibody. Lanes 1 and 3 represent 5% of the total input for each Tyk2 pulldown reaction resulted in *®vefold inhibition of ISGF3 DNAbinding but in a modest *50 ± 80% inhibition of ISG expression (Figure 4) . A possible explanation for this dierence may lie within the transactivation capacity of E6, which is mediated through interactions with the basal transcriptional machinery (Rapp and Chen, 1998) .
We also detected an interaction between E6 proteins and Tyk2. In regard to it, we found that Tyk2 interacts with a larger fraction of HPV-18 E6 than HPV-11 E6 (Figures 6 and 7) . This is consistent with the ability of HPV-18 E6 but not HPV-11 E6 to inhibit IFN-asignaling in HT1080 cells. The E6/Tyk2 interaction appears to be speci®c for Tyk2 since neither STAT2 nor STAT1 was bound to E6 (data not shown). In addition, the E6/Tyk2 interaction may not require Tyk2 activation since the catalytically inactive mutant Tyk2 K930I was still capable of interacting with E6 to the same degree as wt Tyk2 ( Figure 6B ). Binding of E6 proteins to Tyk2 requires the JH 6 -JH 7 domains of Tyk2 ( Figure 8A ), which are also important for Tyk2 interaction with IFNAR1 ( Figure 8B ). Pull down experiments demonstrated that an equal fraction of Tyk2 (5% of the total input) interacts with both HPV-18 E6 and IFNAR1 (Figure 8 ).
Work in many laboratories for the past several years has led to a sequential activation model for IFN-a signaling (Pellegrini and Dusanter-Fourt, 1997) . The IFN-a receptor is present at low numbers on the surface of all cell types and consists of two transmembrane proteins named IFNAR1 and IF-NAR2-2 (Novick et al., 1994; Uze et al., 1990) . The IFNAR2 gene generates several alternatively spliced forms, but only the product harboring a long intracytoplasmic domain (IFNAR2-2) is part of a functional IFN-a receptor (Domanski et al., 1995; Lutfalla et al., 1995) (Figure 9) . A membrane-proximal 33 amino acid sequence of the cytoplasmic domain of IFNAR1 physically associated with Tyk2 (Colamonici et al., 1994a,b) (Figure 9A ). In response to IFN-a, Jak1 and Tyk2 become activated by phosphorylation resulting in the phosphorylation of tyrosine 466 of IFNAR1, which is utilized as a docking site by the SH2 domain of STAT2 Yan et al., 1996) (Figure 9B ). Bound STAT2 to IFNAR1 serves as a substrate of activated Tyk2 resulting in STAT2 phosphorylation on tyrosine 690 , which then provides a docking site for the SH2 domain of STAT1, allowing its tyrosine 701 to become phosphorylated (Greenlund et al., 1994; Improta et al., 1994) (Figure 9B ). According to this model, our ®ndings may be explained by the ability of E6 to interact with Tyk2 and prevent binding of Tyk2 to IFNAR1 ( Figure 9C ). Binding of E6 to Tyk2 may result in an impaired phosphorylation of IFNAR1 on tyrosine 466 and sequentially, in inhibition of STAT2 and STAT1 phosphorylations. There are three lines of evidence that favor this possibility. First, cell fractionation experiments have also shown a cytoplasmic localization of E6 proteins (Rapp and Chen, 1998) . Second, the JH 6 -JH 7 domains of Tyk2 are also required for the interaction with the cytoplasmic portion of the IFNAR1 subunit ( Figure 8B ). Interestingly, the JH 6 -JH 7 domains are required for ecient phosphorylation of IFNAR1 in vitro and for rendering the kinase activable by IFN-a (Gauzzi et al., 1997) . Third, tyrosine phosphorylation of Tyk2 is diminished in cells expressing HPV-18 E6 after stimulation with IFN-a ( Figure 5A ). Although such a mechanism could be explained by a direct association between Tyk2 and E6 in vitro, the possibility that the function of Tyk2/E6 interaction is modulated by other cellular proteins in vivo can not be excluded. Also, the Tyk2/E6 interaction may not result in the destabilization of IFNAR1 since IFNAR1 levels are not aected by the expression of HPV-18 E6 (data not shown).
It should be noted, however, that inhibition of Tyk2 activation by HPV-18 E6 may proceed through more than one but not mutually exclusive mechanisms. In addition to Tyk2/E6 interaction, E6 may also modulate the expression and/or activity of a phosphatase that targets Tyk2 activation (David et al., 1996; You et al., 1999) . It is also conceivable that E6 might be able to regulate the expression and/or activity of a speci®c inhibitor(s) of Tyk2 and/or STAT2. Such inhibitors to the components of the Jak-STAT pathway have been identi®ed and characterized (Starr and Hilton, 1999) .
In regard to Tyk2/E6 interactions, E6 binding to Tyk2 took place when GST-fusion proteins with either HPV-18 or HPV-16 E6 were used (data not shown). Also, HPV-16 E6 but not HPV-18 E6 interacted with Jak2 in vitro (data not shown), which may account for the speci®city of HPV-18 E6 for IFN-a signaling described in this paper. This is consistent with other ®ndings suggesting that the speci®city of Jak kinases may lie in their structural interaction with the IFN receptor and dierent proteins rather than in the substrate speci®city of their kinase domains (Pellegrini and Dusanter-Fourt, 1997) . Such dierences of E6 function among the`high risk' HPV subtypes are not unusual. For example, HPV-16 E6 interacts very strongly with IRF-3 in vitro whereas HPV-18 E6 interacts only modestly with IRF-3 (Ronco et al., 1998) .
A recent study with the`high risk' HPV-16 E6 led to the identi®cation of the conserved binding motif E-L-L/V-G within the E6 interacting proteins E6AP (a ubiquitin protein ligase) and E6BP (a putative calcium binding protein), which is required for interaction with HPV-16 E6 (Elston et al., 1998) . Analysis of the amino acid sequences of Tyk2 identi®ed the presence of a similar sequence E-S-L-G within the JH6 domain of Tyk2 supporting our data that this domain is required for E6/Tyk2 interaction (Figure 8 ). In regard to E6 protein, the structural features necessary for interaction with Tyk2 are not as yet known. E6 is a small basic protein of 151 amino acids whose major structural characteristic is the presence of two hypothetical zinc ®ngers. At the base of each of them are two motifs containing cysteines (Cys-X-X-Cys), which are conserved throughout all HPV types (Howley, 1996; Tommasino and Crawford, 1995) . This structural characteristic of E6 may be necessary but not sucient for the speci®city of Tyk2/E6 interaction since HPV-18 and HPV-11 E6 proteins, which both contain the zinc ®nger structures, bind with dierent anity to Tyk2 (Figures 6 and 7) . The`high risk' HPV E6 has been shown to bind to the tumor suppressor p53 resulting in p53 inactivation by degradation through the ubiquitin pathway (Rapp and Chen, 1998) . Unlike p53, incubation of rabbit reticulocyte lysates containing HPV-18 E6 and Tyk2, STAT1, or STAT2 did not result in degradation of these proteins (data not shown). In addition, Jak-STAT activation was not aected by the expression of a temperature sensitive mutant of p53 in HT1080 cells (data not shown) suggesting that the eect of E6 on Jak-STAT activation is most likely independent of p53 inactivation.
Considering the physiological signi®cance of our ®ndings, the inhibition of Jak-STAT pathway by HPV-18 E6 protein may represent one of the mechanisms utilized by HPVs to block IFN action. Additional mechanisms are likely to exist and proceed through the other major HPV oncoproteins. For example, E7 displays considerable structural and functional similarities to adenovirus E1A protein (Howley, 1996; Tommasino and Crawford, 1995) . E1A functions as a potent suppressor of IFN signaling (Gutch and Reich, 1991; Kalvakolanu et al., 1991; Sen, 1996, 1997; Routes et al., 1996) by interacting with and impairing the transcriptional function of STAT1 (Look et al., 1998) . A systematic approach to investigate the regulation of IFN signaling by the HPV oncoproteins may prove helpful to better understand the molecular basis of HPV-resistance to IFN action and may lead to the development of new strategies to combat HPVinfection and associated diseases.
Materials and methods
Cell culture and transfection
The human epithelial-like cell line HT1080 (ATCC CCL-121) and HeLa S3 (ATCC CCL-2.2) were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) (Gibco) with 10% fetal bovine serum (FBS) (Gibco), 2 mM L-glutamine (Gibco) and 100 units/ml penicillin-streptomycin (Gibco). The HT1080 cells expressing the E6 proteins were established as previously described (Labrecque and Matlashewski, 1995) .
Protein expression with the vaccinia/T7 system
One day before transfection, 0.8610 6 HeLa S3 cells were seeded in 6-cm plates. One hour before transfection, the cells were infected with recombinant vaccinia virus containing the bacterial T7/RNA polymerase gene (Fuerst et al., 1986) . Transfection was performed using 2 mg of plasmid DNA mixed with 5 mg Lipofectamine (Gibco, BRL) per plate and cells were incubated in serum-free media at 378C for 5 h. Subsequently, complete DMEM supplied with serum was added to continue incubation for an additional 16 h before harvesting.
Electrophoretic mobility shift assays (EMSA)
For the EMSAs the following synthetic double-stranded oligonucleotides (Sheldon Biotech. Center, Montreal) were used: the ISRE of the IFN-a-inducible ISG-15 gene (5' -GATCGGGAAAGGGAAACCGAAACTGAAGCC -3'; ISRE is underlined) (Reich and Darnell, 1989 ) and the GAS of the IFN-g-inducible IFP-53 gene (5'-GATCCAGA-TTCTCAGAAA-3'; GAS is underlined) (Strehlow et al., 1993) . Preparation of whole cell extracts, DNA-binding and supershift assays performed as previously described (Wong et al., 1997) . Quanti®cation of the radioactive bands was performed in the linear range of exposure by densitometric analysis using the NIH Image 1.54 software.
Northern blot analysis
The total RNA was isolated by the guanidinium thiocyanate method (Sambrook et al., 1989) . Fifteen mg of RNA was denatured with glyoxal an dimethylsulfoxide and subjected to electrophoresis on a 1.2% agarose gel at 3 V/cm in 10 mM sodium phosphate buer pH 7.0 (Sambrook et al., 1989) .
RNA was then transferred onto a nylon membrane (BioTans, ICN) and probed with a 32 P-dATP-labeled random primed cDNA probes (5610 6 c.p.m./ml) (Sambrook et al., 1989) . The radioactive bands were visualized by autoradiography and quanti®ed in the linear range of exposure by densitometry using the NIH Image 1.54 software.
Immunoprecipitation and Western blot analysis
Protein extraction, immunoprecipitation and immunoblot analysis were performed as previously described (Wong et al., 1997) . For immunoblot analyses the following antibodies were used: (i) anti-STAT1a (Santa Cruz Biotechnology); (ii) anti-STAT2 (Upstate Biotech. Inc.); (iii) anti-Tyk2 (Santa Cruz Biotech); (iv) anti-PTyr (Santa Cruz Biotech.) antibodies; (v) anti-VSV-G antibodies (Boehringer Mannheim); (vi) anti-FLAG antibodies (Sigma). After incubation with anti-mouse or anti-rabbit peroxidase-conjugated antibody (1 : 1000 dilution; Amersham Corp.), proteins were visualized using the enhanced chemiluminescence (ECL) detection system (Amersham Corp.) according to manufacturer's instructions. Quanti®cation of the bands in the linear range of exposure was performed by densitometry using the NIH Image 1.54 software.
GST pull-down and interaction assays GST-E6 fusion proteins were prepared from bacterial cultures induced with 0.1 mM isopropyl-b-D-thiogalactopyranoside (IPTG) (Sigma) for 3 h using the standard protocol (Sambrook et al., 1989) . Cell extracts were prepared with a lysis buer containing 50 mM Tris. HCl pH 8.0, 120 mM NaCl, 0.5% Nonidet P-40 (ICN), 1 mM dithiothreitol (DTT), 0.2 mM PMSF, 4 mg/ml aprotinin, 1 mg/ml leupeptin and 1 mg/ml pepstatin. Pull down experiments were carried out with 1 mg of puri®ed GST-fusion proteins, 100 ± 500 mg of protein extracts and 20 ml of packed glutathione sepharose 1 4B beads (Pharmacia) at 48C for 2 h. The beads were then washed four times with the above lysis buer and subjected to SDS ± PAGE.
Luciferase assays
Cells were transfected with the ISG-15-ISRE-linked luciferase reporter plasmid 15KWTtkGL3 DNA (Pine et al., 1994) . Thirty-six hours after transfection, cells were treated with 1000 IU/ml of IFN-a/b for 6 h. Luciferase activity was measured by Lumat LB9501 (Berthold) equipment using the luciferase assay kit (Promega) according to manufacturer's speci®cation. All transfections were normalized to the bgalactosidase activity.
